HOME › DRUGS › OBILTOXAXIMAB
ACTIVE SUBSTANCE / INN

OBILTOXAXIMAB

Brand name(s): Nyxthracis (previously Obiltoxaximab SFL), ANTHIM
FDA LISTED
EMA LISTED
PRESCRIPTION
WITHDRAWN
Anthrax
BLA125509
ACTIVE SUBSTANCE
Obiltoxaximab
REGULATORS
FDA · EMA
SPONSORS / MAH
SFL Pharmaceuticals Deutschland GmbH, ELUSYS THERAPEUTICS INC
TOTAL APPLICATIONS
2
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
ANTHIMBLA125509ELUSYS THERAPEUTICS INCPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
Nyxthracis (previously Obiltoxaximab SFL)SFL Pharmaceuticals Deutschland GmbHWithdrawn18/11/2020Anthrax

FULL INTELLIGENCE ON OBILTOXAXIMAB

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →